1. Pink Sheet
  2. >>Archive

Deals Of The Week: Pfizer Management Updates Thoughts On Split

 
• By Wendy Diller, Lisa LaMotta, Jessica Merrill, Brenda Sandburg, Paul Bonanos, and Michael Goodman

Pfizer top management hasn’t yet decided whether it will divide in two or stop at a “virtual split.” Plus updates on Lundbeck/Otsuka, Shire/SARcode, AstraZeneca/Actavis, and more.

Pfizer Inc.’s Chairman and CEO Ian Read doesn’t make himself available for interviews readily, so a March 26 note from Sanford Bernstein’s pharma analyst Tim Anderson caught our attention. The note describes a teleconference call Anderson held with Pfizer’s top management team, including Read and R&D chief Mikael Dolsten.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

EU ‘Can’t Expect Industry To Give Up Proprietary Insights’ Under Health Data & Clinical Trials Regulations

 
• By Eliza Slawther

Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.

How Tumult At US FDA Could Impact Merger and Acquisition Strategy

 
• By Joseph Haas and Nielsen Hobbs

With review and development uncertainly increasing, "it’s going to take longer for certain targets … to progress to a place where they’ve been derisked enough that big pharma is ready to write a big check," said Andrew Goodman of Paul Hastings.